Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript Summary
Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript Summary
Net loss for Q3 2024 increased to $7.9 million from $7.2 million in Q3 2023.The following is a summary of the Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript:
以下是Sera Prognostics Inc（SERA）2024年第三季度業績會議記錄摘要：
Financial Performance:
財務表現:
Net revenue for Q3 2024 was $29,000, a decrease from $42,000 in the same period a year ago.
Total operating expenses for Q3 2024 were $8.9 million, up 8% from $8.2 million in Q3 2023.
Net loss for Q3 2024 increased to $7.9 million from $7.2 million in Q3 2023.
2024年第三季度淨營業收入爲29,000美元，較一年前的42,000美元下降。
2024年第三季度總營業費用爲890萬美元，比2023年第三季度的820萬美元增長了8%。
2024年第三季度淨虧損從2013年第三季度的720萬美元上升至790萬美元。
Business Progress:
業務進展:
Focused on publication of clinical trial results and expanding test adoption and payer coverage.
Launched educational campaigns with significant engagement and initiated direct-to-consumer sales through new online platforms.
Continued growth in visibility and adoption through media campaigns and social media presence.
專注於發佈臨床試驗結果並擴大測試採用率和支付者覆蓋範圍。
通過新的在線平台啓動了具有重大參與度的教育宣傳活動，並推出了直接面向消費者銷售。
通過媒體宣傳和在社交媒體上的存在，能夠進一步提升知名度和用戶採用率。
Opportunities:
機會：
Addressing increased rates of preterm births in the U.S., a significant health care challenge, via educational and awareness campaigns.
Expanding direct-to-consumer access to PreTRM tests, enhancing potential for revenue growth.
通過教育和意識活動來應對美國早產率上升，這是一個重要的醫療保健挑戰。
擴大直接面向消費者推廣PreTRm檢測，提升營業收入增長潛力。
Risks:
風險：
Slow scaling of AI services may delay expected revenue growth from these innovations.
人工智能服務的緩慢擴展可能會延遲這些創新預期營業收入增長。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
